IPCA Laboratories

IPCA Laboratories Working Capital

The Working Capital of IPCA Laboratories (IPCALAB.NS) as of Nov 10, 2026 is 20.66 B INR. In the previous year, Working Capital was 44.35 B INR — a change of -53.41% (lower).

Working Capital

20.66 BINR

YoY

-53.41%

Last updated:

Working Capital of IPCA Laboratories is 2026 20.66 B INR. Working Capital of IPCA Laboratories was 2025 44.35 B INR. It decreases by -53.41% lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IPCA Laboratories Stock analysis

What does IPCA Laboratories do? Ipca Laboratories Ltd. generates revenue through the manufacturing and marketing of over 350 pharmaceutical formulations and approximately 80 active pharmaceutical ingredients (APIs), including Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts, and Propranolol. The company sells its branded products such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, and Venpower in more than 100 countries globally. Its subsidiaries, Ipca Pharmaceuticals, Inc., Ipca Laboratories (U.K.) Ltd, and Tonira Exports Limited, support the distribution and sales of these products across international markets. The company's primary customers are healthcare providers, hospitals, and pharmacies in over 100 countries, purchasing both generic APIs and branded formulations. Manufacturing units in India produce APIs and formulations, with the firm's subsidiaries facilitating global market access. The therapeutic segments covered by its products include cardiovascular, antimalarial, and gastrointestinal treatments, among others, driven by the demand for cost-effective pharmaceutical solutions. IPCA Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IPCA Laboratories stock

Working Capital of IPCA Laboratories is 20.66 B INR in 2026.

Working Capital of IPCA Laboratories changed from 44.35 B INR to 20.66 B INR, representing a -53.41% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Working Capital IPCA Laboratories since 2006 – with annual values, charts, and detailed analysis.

Working capital is the difference between current assets and current liabilities. Positive working capital indicates a company can meet its short-term obligations.

Working Capital's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Working Capital's IPCA Laboratories historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — IPCA Laboratories

All Key Metrics — IPCA Laboratories